Welcome to the myoscience, Inc. ("myoscience") web site. Myoscience maintains this Web Site to provide information to and communicate better with physicians, patients, investors, and others who may be interested in learning more about myoscience and the products and services it offers. You may use this Web Site, provided you comply with these terms and conditions.
Please take a few minutes to carefully review these terms and conditions. By accessing and using this Web Site you agree to follow and be bound by these terms and conditions. If you do not agree to follow and be bound by these terms and conditions, you may not access, use or download materials from this Web Site.
Myoscience reserves the right to update or modify these terms and conditions at any time without prior notice. Your use of this Web Site following any such change constitutes your agreement to follow and be bound by the terms and conditions as changed. For this reason, we encourage you to review these terms and conditions every time you use this Web Site. These terms and conditions were last revised on August 25, 2011.
Everything you see and hear on this Web Site (the "Content"), including, for example, all of the text, directories, photographs, illustrations, graphics, audio clips, video clips, and audio-video clips, is copyrighted under United States law and applicable international copyright laws and treaty provisions. The copyrights in the Content are owned by myoscience or by one of its affiliates, or by third parties who have licensed their materials to myoscience. The entire Content of this Web Site is copyrighted as a collective work under United States law and applicable international copyright laws and treaties. Myoscience owns the copyright in the selection, coordination, arrangement and enhancement of the Content. You may download, store, print, and copy selected portions of the Content of this Web Site, provided you:
Only use the Content you download for your personal, noncommercial use or to further your business dealings with myoscience.
Do not publish or post any part of the Content on any other Internet site without obtaining the prior written consent of myoscience.
Do not publish or broadcast any part of the Content in or on any other media without obtaining the prior written consent of myoscience.
Do not modify or alter the Content in any way or delete or modify any copyright or trademark notices or notices of confidentiality. No right, title or interest in the downloaded Content is transferred to you when you download Content from this Web Site. Myoscience reserves all intellectual property rights in any Content you download from this Web Site. Except as expressly stated above, you may not copy, download, print, publish, display, perform, distribute, transmit, transfer, translate, modify, add to, update, compile, abridge or in any other way transform or adapt all or any part of the Content without first obtaining written permission from myoscience.
All of the trademarks, service marks and logos displayed on this Web Site (the "Trademark(s)") are registered and unregistered trademarks of myoscience, one of its affiliates, or third parties who have licensed their Trademarks to myoscience or one of its affiliates. Except as expressly stated in these terms and conditions, you may not reproduce, display or otherwise use any Trademark without first obtaining myoscience's written permission.
This site may contain hyperlinks to web sites that are not operated by myoscience. These hyperlinks are provided for your reference and convenience only, and do not imply any endorsement of the material or services provided on these third-party web sites or any association with their operators. Myoscience does not review or control these web sites and is not responsible for their content. Myoscience expressly disclaims any responsibility for the content of any third party web sites linked to our Web Site or the products or services of such third party. These third-party web sites (and the web sites to which they link) may contain information that is inaccurate, incomplete, or outdated. Myoscience does not make any representations regarding the content or accuracy of materials on such non-myoscience web sites or the products or services of any third party operating such web sites. You access and use these web sites (and the web sites to which they link) solely at your own risk.
Because different countries around the world have different laws and regulatory requirements, some medical devices and treatments are available in some countries and not in others. This Web Site contains references or cross references to myoscience products, programs and services that may not available or announced in your country. These references do not imply that myoscience intends to announce such products, programs or services in your country. Consult your local myoscience sales representative or contact myoscience if you have questions about which products, programs and services may be available to you.
The information provided on this Web Site is not intended nor recommended as a substitute for professional medical advice. Always seek the advice of your physician or other qualified health provider regarding any medical condition or treatment. Nothing contained on this site is intended to be for medical diagnosis or treatment.
THIS WEB SITE IS PROVIDED ON AN "AS IS," "AS AVAILABLE" BASIS, WITHOUT WARRANTIES OF ANY KIND. TO THE FULLEST EXTENT POSSIBLE PURSUANT TO APPLICABLE LAW, MYOSCIENCE AND ITS AFFILIATES DISCLAIM ALL WARRANTIES, EXPRESS, IMPLIED OR STATUTORY, INCLUDING, BUT NOT LIMITED TO, IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, AND NON-INFRINGEMENT OF THIRD-PARTY RIGHTS. WITHOUT LIMITING THE FOREGOING, MYOSCIENCE DOES NOT REPRESENT OR WARRANT THAT THIS WEB SITE WILL BE AVAILABLE AT ANY PARTICULAR TIME OR LOCATION OR THAT ITS OPERATION WILL BE UNINTERRUPTED OR ERROR FREE. MYOSCIENCE DOES NOT REPRESENT OR WARRANT THAT THE CONTENT OF THIS SITE IS FREE OF VIRUSES, WORMS OR OTHER CODE THAT MAY MANIFEST CONTAMINATING OR DESTRUCTIVE PROPERTIES. IF YOUR USE OF THE WEB SITE OR THE MATERIALS RESULTS IN THE NEED FOR SERVICING OR REPLACING EQUIPMENT OR DATA, MYOSCIENCE IS NOT RESPONSIBLE FOR THOSE COSTS. USERS ARE RESPONSIBLE FOR PROTECTING THEMSELVES BY INSTALLING, UPDATING AND RUNNING ANTI-VIRUS PROGRAMS. INFORMATION PUBLISHED ON THIS WEB SITE MAY BE INCOMPLETE OR OUTDATED AND MAY CONTAIN INACCURACIES OR TYPOGRAPHICAL ERRORS. MYOSCIENCE DOES NOT WARRANT OR MAKE ANY REPRESENTATIONS REGARDING THE USE, VALIDITY, ACCURACY, CURRENCY, RELIABILITY OR COMPLETENESS OF, OR THE RESULTS OF THE USE OF, OR OTHERWISE RESPECTING THIS WEB SITE OR ANY INFORMATION, MATERIALS, SERVICES, SOFTWARE, TEXT, GRAPHICS AND LINKS CONTAINED ON OR ACCESSED THROUGH THIS WEB SITE. BECAUSE SOME JURISDICTIONS DO NOT PERMIT THE EXCLUSION OF CERTAIN WARRANTIES, THESE EXCLUSIONS MAY NOT APPLY TO YOU. MYOSCIENCE MAKES NO CLAIMS THAT THE MATERIALS ARE APPROPRIATE OR MAY BE DOWNLOADED OUTSIDE OF THE UNITED STATES. ACCESS TO THE MATERIALS MAY NOT BE LEGAL BY CERTAIN PERSONS OR IN CERTAIN COUNTRIES. IF YOU ACCESS THE WEB SITE FROM OUTSIDE OF THE UNITED STATES, YOU DO SO AT YOUR OWN RISK AND ARE RESPONSIBLE FOR COMPLIANCE WITH THE LAWS OF YOUR JURISDICTION.
YOUR USE OF THIS WEB SITE IS AT YOUR SOLE RISK. UNDER NO CIRCUMSTANCES, SHALL MYOSCIENCE, ITS AFFILIATES OR ANY OF THEIR RESPECTIVE DIRECTORS, OFFICERS, EMPLOYEES, OR AGENTS, BE LIABLE FOR ANY DIRECT OR INDIRECT LOSSES OR DAMAGES ARISING OUT OF OR IN CONNECTION WITH YOUR USE OF OR INABILITY TO USE THIS WEB SITE OR YOUR RELIANCE ON ANY INFORMATION PROVIDED ON THIS WEB SITE. THIS IS A COMPREHENSIVE LIMITATION OF LIABILITY THAT APPLIES TO ALL LOSSES AND DAMAGES OF ANY KIND WHATSOEVER, WHETHER DIRECT OR INDIRECT, GENERAL, SPECIAL, INCIDENTAL, CONSEQUENTIAL, EXEMPLARY OR OTHERWISE, INCLUDING WITHOUT LIMITATION, LOSS OF DATA, REVENUE OR PROFITS. THIS LIMITATION OF LIABILITY APPLIES WHETHER THE ALLEGED LIABILITY IS BASED ON CONTRACT, NEGLIGENCE, TORT, STRICT LIABILITY OR ANY OTHER BASIS AND EVEN IF AN AUTHORIZED REPRESENTATIVE OF MYOSCIENCE OR ITS AFFILIATES HAS BEEN ADVISED OF OR SHOULD HAVE KNOWN OF THE POSSIBILITY OF SUCH DAMAGES.IF ANY PART OF THIS LIMITATION OF LIABILITY IS FOUND TO BE INVALID OR UNEN FORCEABLE FOR ANY REASON, THEN THE AGGREGATE LIABILITY OF MYOSCIENCE AND/OR ITS AFFILIATES UNDER SUCH CIRCUMSTANCES FOR LIABILITIES THAT OTHERWISE WOULD HAVE BEEN LIMITED SHALL NOT EXCEED ONE HUNDRED ($100.00) DOLLARS.
YOU AGREE TO DEFEND, INDEMNIFY, AND HOLD HARMLESS MYOSCIENCE, ITS OFFICERS, DIRECTORS, EMPLOYEES AND AGENTS, FROM AND AGAINST ANY CLAIMS, ACTIONS OR DEMANDS, INCLUDING WITHOUT LIMITATION REASONABLE LEGAL AND ACCOUNTING FEES, RESULTING FROM YOUR USE OF THE MATERIALS (INCLUDING SOFTWARE) OR YOUR BREACH OF THE TERMS OF THIS AGREEMENT. MYOSCIENCE SHALL PROVIDE NOTICE TO YOU PROMPTLY OF ANY SUCH CLAIM, SUIT OR PROCEEDING OF WHICH IT RECEIVES NOTICE AND SHALL ASSIST YOU, AT YOUR EXPENSE, IN DEFENDING ANY SUCH CLAIM, SUIT OR PROCEEDING.
This Web Site is controlled and operated by myoscience from its offices within the State of California in the United States. Any claim relating to these Terms and Conditions and/or the use of this Web Site shall be governed by the laws of California. By using this Web Site, you consent to personal jurisdiction in the federal and state courts of California for any action arising out of or relating to this Web Site, these Terms and Conditions or your use of this Web Site. The federal and state courts of California shall have exclusive jurisdiction over all such actions.
If any provision of these Terms and Conditions is held invalid or unenforceable by any court of competent jurisdiction, the other provisions of these Terms and Conditions shall remain in full force and effect. Any provision of these Terms and Conditions held invalid or unenforceable only in part or degree will remain in full force and effect to the extent not held invalid or unenforceable. No waiver of any term of this Agreement shall be deemed a further or continuing waiver of such term or any other term.
This Agreement constitutes the entire agreement between you and myoscience with respect to your access to and/or use of this Web Site and shall not be modified except by myoscience as provided herein or through a written document signed by both parties.
The only personal data myoscience currently collects through this Web Site is the information you send to us when you contact myoscience with your questions and comments through the Contact Us page on this Web Site. When you send us an e-mail through that page, we ask you for your name and other contact information, including, for example, your company's name, your e-mail address, and your mailing address or the mailing address of your company.
Myoscience does not sell, trade or rent your personal information to others. Myoscience uses the information you provide to respond to your e-mail, answer your question or resolve your problem. Myoscience and our affiliates also use this information to help us improve the content and functionality of our web sites, to better understand our customers and markets, and to improve our products and services. Myoscience and our affiliates may use this information to contact you in the future to tell you about products or services we believe will be of interest to you. If we do so, each communication we send you will contain instructions permitting you to "opt-out" of receiving future communications.
In addition to the information you provide when you use our Web Site, myoscience uses technology to collect anonymous information about the use of our Web Site. For example, we use technology to track how many visitors access our Web Site, the date and time of their visit, the length of their stay, and which pages they view. We also use technology to determine which Web browsers our visitors use and the address from which they accessed our site (for example, if they connected to myoscience.com by clicking on one of our banner ads). This technology does not identify you personally. It simply enables us to compile statistics about our visitors and their use of our Web Site. Myoscience and our affiliates use this anonymous data and share it with third parties to improve the content and functionality of our web sites, to better understand our customers and markets, and to improve our products and services.
In order to collect the anonymous data described in the preceding paragraph, myoscience may use temporary "cookies" that collect the first level domain name of the user (for example, if your e-mail address is "email@example.com," the cookie collects the "xyz.com" portion of your e-mail address) and the date and time you accessed this Web Site. Cookies by themselves cannot be used to discover the identity of the user. A cookie is a small piece of information which is sent to your browser and stored on your computer's hard drive. Cookies keep track of non-personal information such as the URL that you came from and go to next, your navigation through the website (for example, the advertisements that you click on), the browser and operating system that you use, and your IP address. Cookies do not damage your computer. You can set your browser to notify you when you receive a cookie. This enables you to decide if you want to accept it or not. At the present time, myoscience only uses temporary or "session" cookies. These cookies expire when your browser window is closed.
Myoscience does not knowingly collect personal data from children under the age of thirteen. If you are under thirteen, please do not give us any personal data. If you have reason to believe that a child under the age of thirteen has provided personal data to myoscience, please contact us, and we will endeavor to delete that information from our databases.
These terms & conditions are hereby incorporated into any transaction involving the sale, lease, rental, loan or licensing of Products, as defined below, by myoscience, Inc.
1.Definitions. "Authorized User" will mean a Licensed Physician or professional with substantial medical education and training who both: (a) possesses the training and qualifications required by applicable law to use the Products in accordance with this End User Agreement (the "Agreement") and (b) will use the device under company supervision until all training required by myoscience, Inc. ("Company") for the safe and proper use of the Products has been successfully completed within 90 days from Agreement execution and prior to reorder of Smart Tips. "Country of Use" will mean the country to which a Product was originally shipped by Company to the customer ("Customer"). "Licensed Physician" will mean a medical doctor in good standing that is licensed to practice medicine in the relevant jurisdiction at the time of the sale of the Products. "Products" will mean all products, supplies, documentation, training and other items purchased from Company by Customer and may be new or refurbished. Company is under no obligation to continue the manufacture of any Product.
2. Purchase of Products. Customer agrees to purchase and use Products in accordance with this Agreement. The purchase price for Products will be as communicated by Company from time to time and is subject to change at Company's sole discretion. Prices are exclusive of all taxes (including any excise, sales, use, value added, withholding and other taxes), import/export fees, customs duties and tariffs ("Taxes"), all of which will be Customer's responsibility. If Company is required to pay any Taxes, Customer will reimburse Company for all amounts paid. All payments will be made by means acceptable to Company in accordance with Company's then-current policies in.
3. Purchase Orders. This Agreement will exclusively govern all of Customer's orders for Products and will supersede any terms and conditions contained in Customer's purchase orders and other business forms, regardless of any failure of Company to object thereto. Customer will order all Products through a means acceptable to Company. No order will be binding on Company until accepted by Company in writing or Company ships the applicable Products.
4. Use of Products. (a) The Products will be used only by an Authorized User in the Country of Use. Any Authorized User who is not a Licensed Physician will use the Products only under the active supervision of a Licensed Physician. Allowing the use of any Products by any person other than an Authorized User who is, or is acting under the active supervision of a Licensed Physician may violate applicable law and may endanger patient safety. For purposes hereof, "active supervision" means having a Licensed Physician available during the performance of any procedure using the Products. (b) Customer will use, and will ensure that its employees and agents use, the Products only for their intended and approved uses and in accordance with this Agreement and all Company documentation and any updates thereto. (c) Customer will not sell, donate or otherwise transfer any Product to any third party, or export or re-export any Product or any Software contained therein, without Company's prior written consent and without all necessary United States and foreign government consents and licenses. (d) Customer will not tamper with, modify or assist any third party in modifying any Product. Company reserves the right not to sell any Products necessary for the continued use of any Products previously purchased if Company believes the Products are being used in violation of this Agreement.
5. Adverse Events. Customer will promptly (and in any event within two days) report to Company's Customer Service Department any malfunction of a Product or any injury arising out of use of a Product and provide all related information requested by Company.
6. Proprietary Rights. Company retains all proprietary rights, including all patents, copyrights and trade secrets, in and to all designs, engineering details and other technology and information pertaining to the Products. In furtherance of the foregoing, Company retains sole and exclusive ownership of all software included in or provided in connection with the Products (the "Software"), and Company hereby grants to Customer a non-exclusive, non-transferable license to use the Software as incorporated into, and solely for use in connection with, the Products in accordance with this Agreement. For clarity, the Software is licensed, and not sold, to Customer; any references to "sale" or "purchase" in this Agreement with respect to the Software mean the sale or purchase of such license. Customer will not (a) disassemble, decompile or otherwise reverse engineer the Software or any Product or (b) modify, copy, sell, rent, transfer, reproduce or distribute the Software. Upon at least 10 days notice, Customer will grant Company access to Products to install any new versions, updates or upgrades of the Software.
7. Trademarks and Advertising. Customer will comply with Company's trademark and advertising guidelines made available with Company's practice marketing kit and upon request. All goodwill derived from the use of Company trademarks will inure solely to the benefit of Company.
8. Delivery. Products will be shipped to Customer Ex Works (Incoterms 2010) Company's shipping point, at which time title and risk of loss will pass to Customer. Customer will be responsible for all shipping, clearance and forwarding costs. Company will not be liable for any delay in delivery.
9. Training. Customer will ensure that Customer and its employees and agents are fully trained with respect to the Products, and that Customer and its employees and agents comply with all applicable laws and regulations, including those of medical agencies and certification boards. Customer will ensure that its Authorized Users attend all training offered by or on behalf of Company that relates to safe use of the Products.
10. Warranty. Company warrants to Customer that the Products will be free from significant manufacturing defects in materials and workmanship during the Company's standard manufacturer's warranty period stated on the Sales/Lease Order Request. The sole and exclusive remedy of Customer for Company's breach of the foregoing warranty will be, at Company's option, the repair or replacement of a confirmed defective unit and such replacement may be with new or refurbished units. Except with respect to confirmed defective Products in breach of the foregoing warranty, Company conveys no right of return to Customer and no returns will be accepted. The foregoing warranty is contingent upon proper use of the Products by trained and authorized personnel in their intended and approved uses, and the foregoing warranty will not apply to items that were modified or otherwise altered or changed without Company's prior written approval, that were repaired by persons not authorized by Company, that were subjected to unusual physical, electrical or environmental stress or that were damaged during shipment to Customer. Except for the foregoing warranty, Company makes no warranty, express, implied or statutory, as to any matter whatsoever, including any warranty of merchantability, fitness for a particular purpose or non-infringement. The foregoing warranty applies only in favor of Customer who is the end user and original purchaser of the Products and is not transferable. Return of defective Products must be made according to Company's then-current return goods authorization procedures. Company will not accept any returns of sterile Products if the original packaging has been tampered with or opened, without Company's prior approval.
11. Limitation of Liability. Company's total aggregate liability arising out of this Agreement will be limited to the amount of the purchase price for the Product in question. Under no circumstances will Company be liable for any incidental, consequential, indirect, exemplary, punitive or special damages, including damages for lost revenue, profits or business opportunities, the cost of procurement of substitute goods or services or other financial losses. These limitations apply even if Company has been advised of the possibility of such damages, notwithstanding any failure of essential purpose of any limited remedy and regardless of the theory of liability.
12. Term and Termination. This Agreement will commence on the date of the last signature below and will continue in force until Company gives notice of termination. Sections 4–7, 11, and 13–15 will survive any termination, as well as all payment obligations incurred prior to termination.
13. Dispute Resolution. Any claim or dispute arising out of or relating to a Product or this Agreement will be resolved by binding arbitration conducted in the English language by a single arbitrator in San Francisco, California in accordance with the International Arbitration Rules of the American Arbitration Association. Judgment upon the arbitration award rendered by the arbitrator may be entered in any court having jurisdiction thereof. Pending final determination of a claim through arbitration, a party may seek interim or provisional relief from a court of competent jurisdiction as necessary to protect the rights or property of such party.
14. Indemnity. Each party will indemnify the other party against all liabilities, claims and expenses (including reasonable attorneys' fees and other litigation expenses) incurred by that party against third parties arising from any breach or alleged breach of this Agreement by the respective party.
15. Miscellaneous. This Agreement sets forth the entire agreement of the parties regarding its subject matter, and supersedes all prior agreements and understandings relating to such subject matter. This Agreement will be governed by the laws of the State of California, U.S.A., without reference to principles of conflicts of law of any jurisdiction. This Agreement may not be assigned by Customer, by operation of law or otherwise, without Company's prior written consent. Company has the right to assign this Agreement without notice or consent. Any attempted assignment in violation of the foregoing will be null and void. No amendment of this Agreement, nor any waiver of any rights under this Agreement, will be effective unless in writing signed by both parties. If any provision of this Agreement is found to be invalid or unenforceable, the remainder of this Agreement will remain in full force and effect and be interpreted so as best to reasonably effect the intent of the parties.
Brian Farley appointed Chairman of the Board of Myoscience; Edward Kleinhans appointed Interim CEO
May 23, 2018 - Read Press Release
FREMONT, CA (March 12, 2018) – California-based medical technology innovator, Myoscience, Inc. announced today the first closing of a private financing of $10 million from its current investors led by Valiance Asset Management Limited (“Valiance”) and Accuitive Medical Ventures. Included with this financing is the conversion of promissory notes with principal of approximately $21 million. This financing allows needed funds to continue with the commercial roll-out of its products. Myoscience manufactures the ioveraº system, a non-opioid and non-systemic treatment for blocking pain signals from various peripheral nerves.
Cary G. Vance, President and CEO of Myoscience, stated “We are keenly aware that there’s an opioid epidemic in our country and ioveraº has been shown to decrease the use of opioids in the TKA market and generally. We are pleased to have the support from our investors that will enable us to pursue commercial market adoption for ioveraº in advance of TKA procedures and in connection with osteoarthritis to reduce pain and reduce opioid use.”
Proceeds from this financing will be used to expand the Company’s sales force, expand the Company’s product offering and clinical program, increase product manufacturing and for general corporate purposes to help meet the growing demand for the ioveraº technology within the perioperative and chronic pain market segments of the knee.
Jan Pensaert, Board member and CEO of lead investor Valiance stated "We are excited to see expanding market acceptance of Myoscience products in the medical community to better manage pain. Beyond our initial market focus on surgical or chronic knee pain, this technology has broad application for many parts of the body which is consistent with Myoscience’s clinical studies roadmap to validate new treatment indications.”
Myoscience’s iovera° system is a small, hand-held device that uses disposable tips to deliver focused cold to targeted nerves. It has been well proven to be safe and effective as a stand-alone, non-opioid modality for managing chronic, perioperative and acute pain. The iovera° treatment provides immediate, long-lasting pain relief by blocking the nerve’s ability to transmit pain signals without affecting the structure of the targeted nerve. The iovera° system is approved by US FDA for the blocking of pain and for relieving pain and symptoms associated with osteoarthritis of the knee for up to 90 days.
For additional information, please visit www.iovera.com or email us directly at firstname.lastname@example.org.ABOUT MYOSCIENCE Silicon Valley, California-based Myoscience is a privately-held medical device company committed to making its platform technology, the iovera° system, the standard of care for the treatment of peripheral nerves. The iovera° treatment is powered by the Focused Cold Therapy® delivery system, a patented miniaturization of traditional cryotherapy. The ioveraº system is 510k cleared in the U.S. for the blocking of pain, the relief of pain and symptoms associated with osteoarthritis of the knee for up to 90 days and general surgical use. For more information, please visit www.iovera.com. ABOUT CHRONIC AND PERIOPERATIVE KNEE PAIN More than 10 million people in the US suffer from moderate to severe osteoarthritis in the knee joint. These patients typically suffer from chronic pain until the disease progresses to a severe condition when they may receive an implant using the total knee arthroplasty (TKA) procedure. Less than one in ten patients (approximately 900,000 annually) who suffer from osteoarthritis in the knee receive TKA. The iovera technology has been proven to successfully treat both chronic and perioperative pain of the knee through two very robust, level-1 clinical studies 1,2. 1. Radnovich, R. et al. Cryoneurolysis to treat the pain and symptoms of knee osteoarthritis: a multicenter, randomized, double-blind, sham-controlled trial. Osteoarthritis and Cartilage (2017) p1-10. 2. Dasa, V. et al. Percutaneous freezing of sensory nerves prior to total knee arthroplasty. The Knee (2016) p523-528. © 2018 Myoscience. All rights reserved. iovera° and Focused Cold Therapy are trademarks of Myoscience. MKT-0485 REV A Forward-Looking Statements All statements, other than statements of historical fact, that address activities, events or developments that Myoscience intends, expects, projects, believes, hopes or anticipates will or may occur in the future are forward-looking statements. These statements are based upon certain assumptions and assessments made by Myoscience management and are subject to a number of material risks and uncertainties. Actual results may differ materially, and reported results should not be considered as an indication of future performance. The forward-looking statements represent Myoscience’s assumptions and assessments as of the date of this press release, and Myoscience undertakes no obligation to correct, update or revise the forward-looking statements in this press release for any reason. ###
Myoscience closes $10 million financing
March 12, 2018 - Read Press Release
Myoscience receives 510k Clearance for Nerve Stim Enabled Smart Tip
March 5, 2018 - Read Press Release
One hundred twenty patients are to be enrolled in this trial. Patients will be randomized 1:1. Patients in the study arm will receive iovera therapy in the index knee 3 – 7 days before total knee arthroplasty, while patients in the control arm will receive current standard of care (without the iovera therapy).
Dr. William M. Mihalko, M.D., who is the Principal Investigator in this trial, stated: "At Campbell Clinic, we carefully evaluate new technologies to solve challenging clinical issues, and to improve patient outcomes. I am very excited to begin enrolling patients in the iovera° study looking at reducing pain and narcotic use after total knee replacement. I look forward to seeing the data from this study, which I hope will confirm all our findings and experiences to date. We hope the iovera° technology will help us meet one of the significant needs today – reducing the reliance on opioid based pain medication after total knee replacement surgery."
Patients from six orthopedic surgeons’ practices at the Campbell Clinic will participate in this trial, which aims to show that the iovera° therapy can help in significantly reducing opioid consumption after total knee replacement independent of surgical practice.
Cary G. Vance, President and CEO of Myoscience, added “I am very excited to see that we are able to conduct this study at a renowned institution like the Campbell Clinic. Data from this study will demonstrate and confirm that the iovera° technology can be a solution to help address the opioid epidemic in our nation today.”
The iovera° treatment uses the body’s natural response to cold to treat peripheral nerves. A sensory nerve will stop sending pain signals immediately after receiving targeted cold therapy via the iovera° treatment. The effect on the nerve is transient, providing pain relief until the nerve regenerates and its sensory function is fully restored. This pain relief is achieved without the use of habit-forming drugs such as opioids.
For additional information, please visit www.iovera.com or email us directly at email@example.com.
Silicon Valley, California-based Myoscience is a privately-held medical device company committed to making its platform technology, the iovera° system, the standard of care for the treatment of peripheral nerves. The iovera° treatment is powered by the Focused Cold Therapy® delivery system, a patented miniaturization of traditional cryotherapy. The ioveraº system is 510k cleared in the U.S. for the blocking of pain, the relief of pain and symptoms associated with osteoarthritis of the knee for up to 90 days and general surgical use. For more information, please visit www.iovera.com.
ABOUT TOTAL KNEE ARTHROPLASTY
Total knee replacement is one option to relieve pain and to restore function to an arthritic knee. The most common reason for knee replacement is that other treatments (weight loss, exercise/physical therapy, medicines, and injections) have failed to relieve arthritis-associated knee pain.
The goal of knee replacement is to relieve pain, improve quality of life, and maintain or improve knee function. The procedure is performed on people of all ages, with the exception of children, whose bones are still growing. It is important to have significant pain and/or disability prior to considering this procedure. Because the replacement parts can break down over time, and healthcare providers generally recommend delaying knee replacement until it is absolutely necessary.
Approximately 700,000 knee replacement procedures are performed annually in the US. This number is projected to increase to 3.48 million procedures per year by 2030(1).1. Kurtz S, Ong K, Lau E, et al. Projections of primary and revision hip and knee arthroplasty in the United States from 2005 to 2030. J Bone Joint Surg Am 2007; 89:780.
© 2017 Myoscience. All rights reserved. iovera° and Focused Cold Therapy are trademarks of Myoscience. MKT-0463 REV A
Myoscience to study opioid reduction in post-surgical knee patients; Patient Enrollment has commenced
October 25, 2017 - Read Press Release
“The iovera° technology has the potential to change the current paradigm of pain management for osteoarthritis”, said Dr. Vinod Dasa. “The patients that I have treated with this technology have experienced immediate and long-lasting pain relief; and are grateful to have an option that is non-narcotic and non-systemic.”The FDA clearance was based on a recent prospective, multi-center, sham-controlled, randomized, double-blind study of 180 subjects. The study concluded that patients treated with the iovera° device reported statistically significant greater reduction in pain and improvement in symptoms (p=0.001) when compared to patients who received the sham treatment (3). Also, patients who received the iovera° treatment reported pain relief lasting up to 90 days, accompanied by reduced stiffness and improved physical function.
Cary Vance, President and CEO of Myoscience, stated that “The addition of osteoarthritis to the indications for the iovera° treatment will help in extending our innovative non-opioid therapy to more patients, especially in the growing baby-boomer population. I anticipate this technology to become the non-narcotic and non-systemic solution of choice to manage knee pain.”The iovera° treatment uses the body’s natural response to cold to treat peripheral nerves. A sensory nerve will stop sending pain signals immediately after receiving targeted cold therapy via the iovera° treatment. The effect on the nerve is transient, providing pain relief until the nerve regenerates and its sensory function is fully restored. This pain relief is achieved without the use of habit-forming drugs such as opioids.
FDA clears new indication for Myoscience's iovera° system to relieve pain and symptoms associated with osteoarthritis of the knee
May 17, 2017 - Read Press Release
FREMONT, CA (PR Newswire - April 17, 2017) - Myoscience, Inc., a medical device company located in the greater Bay Area, today announced the appointment of Cary G. Vance as President and Chief Executive Officer (CEO), effective April 17, 2017.“The Board is very pleased to announce Cary’s appointment as the new CEO of Myoscience,” said Anthony Lando, a Board Director for Myoscience who also represents a lead investor, Accutive Medical Ventures. Mr. Lando added: “He brings a wealth of experience leading medical device companies to success and has a demonstrated track record of transforming businesses and driving sustained growth. I am confident that Cary is the right person to lead Myoscience to commercial and strategic growth.” “We are delighted that Cary will be leading the Myoscience team,” said Jon Serbousek, Board Director for Myoscience. “The Focused Cold Therapy® delivery system provides a new, non-opioid, pain management option to assist patients in recovering from surgical and non-surgical procedures. The effect is immediate and long lasting.” Mr. Vance has nearly 30 years of leadership experience in the medical device sector. Most recently, Mr. Vance served as President and Chief Executive Officer at Hansen Medical, where over a 2-year period, he led a turnaround effort that resulted in the successful sale of the company. Prior to Hansen Medical, Mr. Vance was at Teleflex Inc., where he served as President of the Anesthesia & Respiratory global business, and as Executive Vice President North America. Additionally, Mr. Vance held executive roles at Covidien, where he served as Vice President & General Manager of Interventional Oncology – America, and as Vice President & General Manager of Energy-based Devices. Earlier in his career, Mr. Vance was with GE Healthcare, where he worked in a series of roles with progressive responsibility, principally in diagnostic imaging sales, sales and marketing management, and executive leadership. He holds a B.A. in Economics and an M.B.A. from Marquette University. “I am very excited to join the Myoscience team to build commercial success using this innovative and remarkable technology for pain management, while also reducing patients’ need for opioid medications,” said Mr. Vance, CEO of Myoscience. “The patented iovera° product platform has the demonstrated ability to improve patients' lives that is unmatched in pain management applications. We have a strong team of dedicated professionals that will continue to drive Myoscience to great success,” noted Mr. Vance. ABOUT MYOSCIENCE California-based Myoscience is a privately-held medical device company dedicated to improving patients’ lives by providing innovative, clinically proven pain treatments. Its iovera° system is powered by patented Focused Cold Therapy® technology. The iovera° system is cleared in the US for the blocking of pain. For more information, please visit www.myoscience.com, or www.iovera.com.
Cary G. Vance appointed President and Chief Executive Officer of Myoscience
April 17, 2017 - Read Press Release
Myoscience to Present New Data at the American Association of Hip and Knee Surgeons Annual Meeting
November 7, 2016 - Read Press Release
Myoscience to participate in Webcast on Pain targeting mechanism
October 3, 2016 - Read Press Release
Breakthrough pain therapy device, iovera°, reaches max enrollment for two knee pain studies ahead of schedule; makes strong entry into orthopedic market
March 1, 2016 - Read Press Release
Myoscience Expands Platform Technology for Pain Treatments to Reach Deep Peripheral Nerves
September 9, 2015 - Read Press Release
Myoscience Headquarters Moves to Fremont California - Primed for Growth
July 24, 2015 - Read Press Release
New York City Pain Specialists Introduce New Treatment for Knee Pain First Physicians in Northeast to offer iovera° treatment
February 23, 2015 - Read Press Release
Los Angeles-area Orthopedic Groups Become First in the Region to offer the iovera° treatment for Patients with Knee Pain
January 22, 2015 - Read Press Release
Jeffrey Gold appointed Chief Executive Officer of myoscience
November 3, 2014 - Read Press Release
Next advancement for the iovera° beauty treatment
October 1, 2014 - Read Press Release
iovera° harnesses cold to block nerve signals and reduce painRedwood City, CA – September 24, 2014 myoscience announced today the launch of its iovera° system for the treatment of anterior and interior knee pain at three practices in the San Francisco Bay area: Remedy Medical Group, Fremont Holistic Center and California Spine Care. The iovera° system, cleared by the FDA to treat peripheral nerve pain, utilizes its patented Focused Cold Therapy™ delivery system to apply a controlled cold zone via a Smart Tip to specific nerves for precise and predictable pain relief. “We are pleased that these Bay Area pain specialists are joining the growing ranks of leading facilities in the nation offering the iovera° system for knee pain sufferers,” said Jeff Gold, myoscience President and Chief Operating Officer. “The iovera° treatment gives physicians the opportunity to safely address their patients’ peripheral nerve pain – the immediate result allows them to see the relief and the subsequent excitement first hand.” Frequent knee pain affects approximately 25% of adults, limits function and mobility, and impairs quality of life.1 Peripheral nerves treated with the iovera° system stop signaling pain for a set period of time, usually up to 3 months, after which their function is restored. Because peripheral nerve function is disrupted rather than destroyed, the treatment is safe, effective and temporary. “iovera° is unique in that it offers safe, highly targeted pain relief right at the peripheral nerve involved in a patient’s pain,” said David Smolins, M.D., Remedy Medical Group. “It’s exciting to see so many of my patients come in with debilitating knee pain and walk out of my office pain-free after their first iovera° treatment.” “Our patients are delighted to have the option of a non-invasive, drug-free treatment that specifically targets the area of pain,” said Santi Rao, M.D., California Spine Care. “We are finding that if patients can avoid or reduce their use of systemic medicines and their side effects, they prefer that option.” “Our patients are achieving immediate and sustained pain relief which allows them to comfortably pursue and make progress in physical therapy, but also, and perhaps more importantly, get back to the activities that matter most to them,” said Barry Shibuya, M.D, Founder and Medical Director, Fremont Holistic Center. The iovera° system delivers liquid nitrous oxide from a convenient and powerful handheld device to the closed-end probes of the Smart Tip during treatment. While this highly pressurized liquid travels from the hand piece to the Smart Tip, it undergoes a phase change and becomes very cold, drawing in heat energy from the surrounding tissue and forming a precise zone of cold at the targeted nerve. The gaseous nitrous oxide returns into the hand piece, leaving nothing behind in the body. This precise cold treatment causes a reversible nerve block based on a process called Wallerian degeneration. Pain is relieved in sensory nerves, which send messages to the central nervous system. Pain relief can last up to 3 months, at which time predictable restoration of nerve function occurs. About iovera° The Food and Drug Administration (FDA) cleared the iovera° system for use in peripheral nerves in January 2013. The iovera° system is being used most frequently for knee pain but can be used to treat pain in any peripheral nerve. The iovera° system is specifically cleared to destroy tissue during surgical procedures by applying cold temperature. It can also be used to produce lesions in peripheral nervous tissue by the application of cold to the selected site for the blocking of pain. The iovera° system is not indicated for treatment of central nervous system tissue. www.ioverahealth.com About Fremont Holistic Center Fremont Holistic Center, located in Fremont, CA, integrates the best of Western and non-Western practices through a therapeutic relationship to care for the entire person (mind, body and spirit). For more information about Fremont Holistic Center please visit: http://www.fremontholistic.com. Patients interested in iovera° treatment at the center can call: 510-585-3055. About Remedy Medical Center Remedy Medical Center, with offices in Redwood City and San Francisco, CA, understands that patient health and wellness begins today. The Center’s medical team has been selected and organized in order to effectively practice all aspects of Physical Medicine and Rehabilitation, and Pain Management. Remedy provides diagnosis, medication management, interventional care, patient education, as well as alternative therapies. For more information about Remedy Medical Center please visit: http://www.remedydocs.com. Patients interested in iovera° treatment at the center can call: 415-819-6575. About California Spine Care California Spine Care, located in San Francisco, Concord and Sacramento, CA, is dedicated to the care and treatment of people with neck, back and joint pain. The center provides a thorough evaluation, comprehensive diagnosis, and treatment plan for its patients. They specialize in non-surgical techniques, injection treatments, as well as state of the art surgery options. For more information about California Spine Care please visit: Patients interested in iovera° treatment at the center can call: 925-691-1700. About myoscience Silicon Valley, California-based myoscience is a privately-held medical device company committed to making its platform technology, Focused Cold Therapy, the standard of care for the treatment of peripheral nerve conditions. Focused Cold Therapy is the patented technology delivered by the ioveraº system. The ioveraº system is currently approved in Europe and Canada for temporary wrinkle reduction, temporary pain reduction and treatment of dermatologic conditions, and is indicated in the United States for use in pain management and general surgical use. For more information, please visit www.myoscience.com. © 2014 myoscience. All rights reserved. iovera° and Focused Cold Therapy are trademarks of myoscience. 1 Nguyen, Uyen-Sa D.T., DSc, et al. “Increasing Prevalence of Knee Pain and Symptomatic Knee Osteoarthritis,” Ann Intern Med. (2011 December 6); 155(11): 725–732.
Bay Area Pain Specialists Freeze Out Knee Pain Becoming Among the First Clinics Nationwide to Offer the iovera° treatment
September 24, 2014 - Read Press Release
iovera˚ harnesses cold to block nerve signals and reduce painRedwood City, CA – July 16, 2014 myoscience announced today the launch of its iovera° system for the treatment of anterior and interior knee pain at the Louisiana State University (LSU) Department of Orthopaedic Surgery. The iovera° system utilizes its patented Focused Cold Therapy™ delivery system to direct a controlled cold dosage via closed-end probes to specific nerves for precise and predictable pain relief. “We are excited that LSU is among the first cutting edge orthopaedic facilities in the nation to offer the iovera° system for knee pain sufferers,” said Clint Carnell, myoscience CEO and iovera° developer. “iovera° gives physicians the opportunity to address their patients’ peripheral nerve pain in a very targeted way harnessing the natural power of cold to temporarily stop nerves from signalling and to deliver immediate toxin-free, drug-free pain relief.” Frequent knee pain affects approximately 25% of adults, limits function and mobility, and impairs quality of life.1 Peripheral nerves treated with the iovera° system stop signalling pain for a set period of time, usually up to 3 months, after which their function is fully restored. Because peripheral nerve function is disrupted rather than destroyed, the results are safe, effective and temporary. “This technology has the potential to change the current paradigm of acute and chronic pain management. The patients that I have treated are all grateful to have an option that is very safe and that has allowed them to get back to functionality quickly,” said Vinod Dasa, MD, Assistant Professor of Clinical Orthopaedics at the Louisiana State University Health Sciences Center (LSUHSC) School of Medicine in New Orleans, one of the first U.S. physicians to perform the procedure and to treat more than 60 patients. “Focused cold therapy offers reliable pain relief in areas such as the knee which may allow for physical therapy to proceed, and even reduce the need for systemic pain relievers.” The iovera° system delivers liquid nitrous oxide from a convenient and powerful handheld device to the closed-end probes of the Smart Tip during treatment. While this highly pressurized liquid travels from the hand piece to the Smart Tip, it undergoes a phase change and becomes very cold drawing in heat energy from the surrounding tissue and forming a precise zone of cold at the targeted nerve. The gaseous nitrous oxide returns into the hand piece, leaving nothing behind in the body. This precise cold treatment causes a reversible nerve block based on a process called Wallerian degeneration. Pain is relieved in sensory nerves, which send messages to the central nervous system. Pain relief can last up to 3 months, at which time predictable restoration of nerve function occurs. About iovera° The Food and Drug Administration (FDA) cleared the iovera° system for use in peripheral nerves in January 2013. The iovera° system is specifically cleared to destroy tissue during surgical procedures by applying cold temperature. It can also be used to produce lesions in peripheral nervous tissue by the application of cold to the selected site for the blocking of pain. The iovera° system is not indicated for treatment of central nervous system tissue. About LSU Department of Orthopaedic Surgery The Department of Orthopaedic Surgery at LSUHSC in New Orleans is dedicated to training excellent orthopaedic surgeons while providing exemplary patient care. The department has many internationally recognized faculty members. The faculty is fellowship-trained in all specialties and is dedicated to continued scholarly activities. Many faculty members are involved in innovative research. A unique feature of the LSU orthopaedic department is the multi-disciplinary approach to treating orthopaedic conditions and the treatment of the ‘whole’ patient for maximum function. For more information about The Department of Orthopaedic Surgery at LSUHSC, a member of the LSU Healthcare Network, please visit: http://www.lsuhn.com/. Patients interested in iovera° treatment at LSUHSC can call: 504.412.1700. About myoscience Silicon Valley, California-based myoscience is a privately-held medical device company committed to making its platform technology, Focused Cold Therapy, the standard of care for the treatment of peripheral nerve conditions. Focused Cold Therapy is the patented technology delivered by the ioveraº system. The ioveraº system is currently approved in Europe and Canada for temporary wrinkle reduction, temporary pain reduction and treatment of dermatologic conditions, and is indicated in the United States for use in pain management and general surgical use. For more information, please visit www.myoscience.com.
Louisiana State University Department of Orthopaedic Surgery Becomes One of the First Clinics Nationwide to Offer iovera˚ Focused Cold Therapy to Freeze Out Knee Pain
July 16, 2014 - Read Press Release
myoscience Named Winner of the 2014 Red Herring Top 100 North America Award
May 21, 2014 - Read Press Release
Forbes Living Features iovera° by myoscience, Inc.
May 20, 2014 - Read Press Release
myoscience, inc. is a Finalist for the 2014 Red Herring Top 100 North America Award
May 7, 2014 - Read Press Release
Novel pain treatment is now available: iovera° system harnesses the power of cold to block pain
May 1, 2014 - Read Press Release
Jeffrey Gold joins myoscience as President and Chief Operating Officer
April 23, 2014 - Read Press Release
ENDSNotes to editors: About myoscience Silicon Valley, California-based myoscience is a privately-held medical device company committed to making its platform technology, Focused Cold TherapyTM, the standard of care for the treatment of peripheral nerve conditions. Focused Cold Therapy is currently approved in Europe and Canada for temporary wrinkle reduction, temporary pain reduction and treatment of dermatologic conditions. The myoscience technology has also been cleared in the United States for use in pain management and general surgical use. For more information, please visit www.myoscience.com.
Vancouverites looking for natural beauty
April 10, 2014 - Read Press Release
ENDSNotes to editors: About myoscience Silicon Valley, California-based myoscience is a privately-held medical device company committed to making its platform technology, the Focused Cold TherapyTM delivery device, the standard of care for the treatment of peripheral nerve conditions. The Focused Cold Therapy delivery device is currently approved in Europe and Canada for temporary wrinkle reduction, temporary pain reduction and treatment of dermatologic conditions. The myoscience technology has also been cleared in the United States for use in pain management and general surgical use. For more information, please visit www.myoscience.com.
Germans looking for natural beauty
April 8, 2014 - Read Press Release
ENDSNotes to editors: About myoscience Silicon Valley, California-based myoscience is a privately-held medical device company committed to making its platform technology, Focused Cold TherapyTM, the standard of care for the treatment of peripheral nerve conditions. Focused Cold Therapy is currently approved in Europe and Canada for temporary wrinkle reduction, temporary pain reduction and treatment of dermatologic conditions. The myoscience technology has also been cleared in the United States for use in pain management and general surgical use. For more information, please visit www.myoscience.com.
Londoners looking for natural beauty
March 27, 2014 - Read Press Release
Myoscience to Present at the Canaccord Genuity Musculoskeletal Conference
February 25, 2014 - Read Press Release
Myoscience to Present at the Cowen and Company 34th Annual Health Care Conference
February 21, 2014 - Read Press Release
REDWOOD CITY, CA (January 7, 2014) – Myoscience is pleased to announce that the iovera°® system has won in the medical category of the GOOD DESIGNTM competition. GOOD DESIGN recognizes the world’s most important consumer design products and is one of the most prestigious and oldest design awards. The awards are organized annually by The Chicago Athenaeum Museum of Architecture and Design in cooperation with the European Centre for Architecture, Art, Design and Urban Studies. Over 700 new products and graphic designs were selected from more than 38 countries for categories including electronics, robotics, children’s products and transportation. The winning entries were awarded for innovation in a variety of areas such as sustainability, creativity, human impact, technology and universal design. The iovera° system, developed by myoscience, inc. harnesses the power of cold using Focused Cold TherapyTM, the advanced technology that powers the device. The iovera° treatment works immediately for both health and beauty applications without leaving any toxins or chemicals behind in the body. The iovera° system is approved in the European Union and Canada for the treatment of wrinkles, and is FDA cleared for the treatment of pain in the United States. “The iovera° system was designed to change the way that physicians address the temporary treatment for pain and wrinkles,” says myoscience CEO Clint Carnell. “The Focused Cold Therapytechnology enables physicians to treat using only the power of cold delivered with a simple and intuitive one-button device. The engineers and designers at LUNAR worked hard in collaboration with the myoscience team to ensure we created a beautiful and effective product.” This is the second design award for the iovera° system, following on the heels of the Spark! Design award, where the iovera° system received the highest honors in the general consumer design category. To see the full list of awards: http://www.chi-athenaeum.org/gdesign/2013/GOOD_DESIGN_2013_MASTER-list.pdf To see the press release from GOOD DESIGN: http://www.chi-athenaeum.org/gdesign/2013/GOOD_DESIGN_2013_PRESS_INFO.pdf ABOUT THE GOOD DESIGNTM AWARD GOOD DESIGN ™ is the world’s most prestigious, recognized, and oldest Design Awards program organized annually by The Chicago Athenaeum Museum of Architecture and Design in cooperation with the European Centre for Architecture, Art, Design and Urban Studies. GOOD DESIGN covers new consumer products designed and manufactured in Europe, Asia, Africa, and North and South America. http://www.chi-athenaeum.org/gdesign/index.html ABOUT MYOSCIENCE Silicon Valley, California-based myoscience is a privately-held medical device company committed to making its platform technology, Focused Cold TherapyTM, the standard of care for the treatment of peripheral nerve conditions. Focused Cold Therapy is the technology underlying the iovera° treatment, which is currently approved in Europe and Canada for temporary wrinkle reduction, temporary pain reduction and treatment of dermatologic conditions. The iovera° system has also been cleared in the United States for use in pain management and general surgical use. For more information, please visit www.myoscience.com. © 2013 myoscience. All rights reserved. iovera° and Focused Cold Therapy are trademarks of myoscience.
iovera° wins Good Design Award
January 7, 2014 - Read Press Release
myoscience to Present at the Piper Jaffray 25th Annual Health Care Conference
November 21, 2013 - Read Press Release
REDWOOD CITY, CA (November 20th, 2013) – Myoscience is pleased to announce that the design for the iovera° system has won top honors in the Spark International design competition. The iovera° system was awarded the highest honor (Spark!) in the category of product design, which is a general category that includes medical devices as well as consumer electronics, cookware, and even sports equipment. Myoscience collaborated with LUNAR to design the iovera° system. “We’re honored to have worked with myoscience to design a beautiful and effective device that will help improve the quality of life for countless people,” says Jeff Salazar at LUNAR. The Spark Awards are given based on two primary criteria: the design innovation and creativity, and the impact it will have on quality of life. The iovera° system is a new take on the safe and reliable use of cold in medicine; by miniaturizing and refining the delivery system to be smaller and more precise, the treatments can be tailored to specific indications. The iovera° system has already improved the quality of life for many who have been treated, immediately reducing pain and enabling people to return to their favorite activities as well as smoothing forehead wrinkles for improved appearance. The iovera˚ system, developed by myoscience, inc. in California, harnesses the power of cold using Focused Cold TherapyTM, the advanced technology that powers the device. The iovera° treatment works immediately for both health and beauty applications without leaving any toxins or chemicals behind in the body. iovera° is approved in the European Union and Canada for the treatment of wrinkles, and is used for the treatment of pain in the United States. “We designed the iovera° system to be sophisticated and intuitive,” says myoscience CEO Clint Carnell. “It has only one button and fits ergonomically in the physician’s hand. Our talented team of engineers and the team of designers at LUNAR who worked hard to ensure we created a product that is not only beautiful to look at, but delivers an elegant result that will immediately ease pain or reduce wrinkles. I am very proud of my team at myoscience who made this concept into a reality.” To see the full list of awards: http://www.sparkawards.com/about/news/ To see the press release from Spark: http://www.prweb.com/releases/2013/11/prweb11336709.htm ABOUT THE SPARK AWARD The Spark mission is to promote better living through better design. The criteria are the same for all Spark competitions: does the design “Spark,” i.e., innovate, change the game and in some way help humanity or the environment we live in. The Spark founders believe Design is an important, relevant tool to help build a better world. We feel that Design and designers act as catalysts, addressing problems and improving our lives and our Earth. www.sparkawards.com ABOUT MYOSCIENCE Silicon Valley, California-based myoscience is a privately-held medical device company committed to making its platform technology, Focused Cold TherapyTM, the standard of care for the treatment of peripheral nerve conditions. Focused Cold Therapy is the technology underlying the iovera° treatment, which is currently approved in Europe and Canada for temporary wrinkle reduction, temporary pain reduction and treatment of dermatologic conditions. iovera° has also been cleared in the United States for use in pain management and general surgical use. For more information, please visit www.myoscience.com. © 2013 myoscience. All rights reserved. iovera° and Focused Cold Therapy are trademarks of myoscience. MKT-0106A
iovera° wins Spark Design Award
November 20, 2013 - Read Press Release
myoscience to Present at the Canaccord Genuity Medical Technology & Diagnostics Forum
November 11, 2013 - Read Press Release
iovera° treatment for dynamic wrinkles now offered by Drs. Jean & Alastair Carruthers and Doctor Shannon Humphrey
September 17, 2013 - Read Press Release
Peter Osborne joins myoscience as Chief Financial Officer
September 16, 2013 - Read Press Release
myoscience Announces $25 million Series E Financing Round
September 12, 2013 - Read Press Release
iovera° treatment for dynamic wrinkles now approved in Canada
July 18, 2013 - Read Press Release
iovera˚ introduced in Europe as the World’s First Toxin-free Treatment for Dynamic Facial Lines
April 4, 2013 - Read Press Release
iovera° Approved in Europe, Gains CE Mark
February 13, 2013 - Read Press Release
FDA Clearance for Pain Management in Nerve Tissue
January 22, 2013 - Read Press Release
myoscience to Present at 2012 Canaccord Genuity Medical Technology Forum
myoscience, inc., the developer of Focused Cold Therapy for the treatment of the peripheral nerve conditions, announced that President & CEO, Clint Carnell, will be presenting at the Canaccord Genuity Medical Technology and Diagnostics Forum to be held on Tuesday, December 4, 2012 at the Le Parker Meridien in New York, NY.
Clint Carnell will speak at 10:00am Eastern time about the upcoming 2013 European Union launch of the company's first aesthetics product for the treatment of wrinkles. Mr. Carnell will also provide an overview of Focused Cold Therapy and the opportunities in therapeutics such as pain and various movement disorders.
The presentation will be webcast live and may be accessed by visiting the myosience website at www.myosience.com
Canaccord Genuity 2012 Medical Technology Forum
November 27, 2012 - Read Press Release
FDA Clearance for Next-Gen Device by myoscience
July 10, 2012 - Read Press Release
Myoscience Closes $33 Million Series D Financing
March 21, 2012 - Read Press Release
Canadian Approval of Cryotherapy Technology
December 15, 2011 - Read Press Release
CE Mark for Novel Cryotherapy Technology
December 7, 2011 - Read Press Release
CBS 4New Orleans (WWL) — Dr. Posas discusses helping a patient who had suffered from severe headaches for over 5 years.
WCBSNEW YORK (WCBS) — Freeze the Pain Away. A report from WCBS's Dr. Max Gomez. An avid runner blows her knee out, "she had the knees of a 90 year old man". Nick with a torn ACL and in spite of three surgeries was in constant pain. Dr. Danesh at Mount Sinai Hospital uses iovera's Focused Cold Therapy to freeze the pain away.
KNBCLOS ANGELES (NBCLA) — When you have chronic knee pain, everything you do hurts. NBC 4's Dr. Bruce Hensel reports on an alternative to addictive pain medicine and surgery. Watch Dr. Williams dramatically improve the knee pain of Sharon Basham-Dominguez by freezing nerves in both knees. This was the first time she felt normal, after years of pain.
THE DOCTORSA ground breaking treatment that can virtually eliminate your pain in 60 seconds. You won't believe what doctors are using today to treat knee pain, headaches, and more. Is it right for you? Over 100 million Americans suffer from pain. Jennifer, she was another statistic until she found another way. Dr. Vernon Williams shows us a new procedure that actually freezes pain away.
CBS NEW YORKNEW YORK (CBSNewYork) — Imagine having knee pain for decades, and then having it all disappear with a quick trip to the doctor's office. As CBS 2's Emily Smith reports, doctors are actually freezing away the pain. Watch Dr. Vinod Dasa treat patient Leslie Griffin who has suffered from knee pain since she was 20 years old.
The iovera° beauty treatment is not available in the United States.
LONDON BEAUTY HUBBEAUTY & LIFESTYLE NEWS — The majority of women in London (54%) claim they would be unlikely to go out and meet friends without doing their hair and makeup yet they are not alone as 43% of men confessed that they would not go out without doing their hair. The findings are from a survey of more than 500 Londoners that reveals unique insights into the way men and women in the capital feel about their beauty and grooming regimes. Read Article
PLASTIC SURGERY PRACTICETHE FACE: IT'S FAUX TOX TIME — iovera° from Myoscience, Redwood City, Calif, delivers Focused Cold Therapy™ as an attractive option for people who want to treat their dynamic forehead wrinkles without a toxin. Currently, it is approved in Europe and Canada for temporary wrinkle reduction, temporary pain reduction, and the treatment of dermatologic conditions. iovera° has also been cleared in the US for pain management and general surgical use. Read Article
WOW NOWFREEZE IT! — The latest beauty trend that's taking plastic surgery clinics by storm vows to offer a natural and rejuvenated result. In essence, this treatment reduces and softens wrinkles without the use of toxins with instant results in just fifteen minutes! In turn, this allows you to resume to the normal, busy schedule of your everyday life. View Article
MY FACE MY BODYTHE NATURAL BEAUTY TREND IN LONDON — A survey conducted by new cosmetic wrinkle treatment iovera°® has found that there is a growing desire among Londoners for more natural beauty products and treatments. Two thirds of respondents (65%) said that they have become more aware of the ingredients in cosmetics and beauty products in the last two years. While quality (59%) and price (48%) are important, natural ingredients (32%) ranked highly on factors influencing purchasing decisions. Read Article
EXPRESSFAT-FREEZING, SHOCK WAVES AND LIGHTBULB FACIALS: THE BRAND NEW BEAUTY TREATMENTS FOR 2014 — Toxin-free wrinkle buster: One of the most tried and tested ways to keep wrinkles at bay is by using a neurotoxin injectable such as Botox. However while this treatment is safe, for many women the thought of injecting toxins and other chemicals into their body is still a big no-no. A new anti-ageing treatment called iovera° may provide a solution. The new 15-minute procedure uses liquid nitrous oxide to temporarily freeze the nerves that move the muscles in the face, helping to smooth lines and wrinkles. Read Article
< src="images/news_beauty_th_prime.jpg" />
PRIMETHE EFFICACY OF FOCUSED COLD THERAPY ON HORIZONTAL DYNAMIC FOREHEAD WRINKLES — Vincent Wong and Fabien Giausseran discuss patient improvement and satisfaction following treatment to forehead wrinkles with a Focused Cold Therapy device. Read Article